Together with 5 other Early Stage Researchers (to be recruited by University of Copenhagen (UCPH), Uppsala University (UU), Johannes Gutenberg – University (JGU) and BioArctic (BA)) you will contribute to the implementation of PET-AlphaSy’s Work package 1 which focuses on positron emission tomography (PET) imaging of α-synuclein with biologicals like monoclonal antibodies.
Within WP1 you will develop dual-labeling techniques of biologicals targeting α-synuclein. The biologicals will come from the pharmaceutical partners within the consortium. After in vitro evaluation, you will evaluate the new PET tracers in vivo together with one of the other PhD fellows hired for this project..
Mobility within the PET-AlphaSy European Training Network is of high importance and you are therefore expected to spend 3 months at Uppsala University and 3 months at H. Lundbeck A/S.
The candidates will be enrolled at the ONWAR (Graduate School Neurosciences Amsterdam Rotterdam, www.onwar.nl) at the VUmc. The graduate program requires the student to obtain 30 ECTS points during the PhD trajectory in order to graduate.
We are looking for a dedicated and skilled individual with excellent analytical skills, good command of written and spoken English and should be able to work in a team as well as independently. You also have the following qualifications:
- Obtained a MSc degree in biology, pharmacology, chemistry or equivalent;
- Experience in radiochemistry (89Zr) with biologicals is prefered.
- Experience with in vitro methodology
- The researcher must not have resided or carried out his/her main activity (work, studies, etc.) in the Netherlands for more than 12 months in the 3 years immediately prior to his/her recruitment – unless as part of a procedure for obtaining refugee status under the Geneva Convention .
- The researcher must be Early Stage Researcher (ESR): at time of recruitment he/she must be in the first 4 years (full-time equivalent research experience) of his/her research careers and must not have been awarded a doctoral degree.
Your work environment
This is one of three PhD fellowships that is available at the Tracer Center Amsterdam, Department of Radiology & Nuclear Medicine of VUmc, The Netherlands, with an anticipated start on February 1st 2019.
The stipend is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813528, the project is called ‘PET-AlphaSy’.
About the Tracer center Amsterdam and the Department of Radiology & Nuclear Medicine
The department of Radiology & Nuclear Medicine is, amongst others, specialized in conducting research using nuclear imaging techniques, more specifically Positron Emission Tomography (PET). Our aim is to use PET for diagnosis of disease, treatment monitoring and patient selection. Tracer Center Amsterdam develops the new PET tracers needed in the clinic for neurological diseases as well as oncology, rheumatology and cardiology. The research of TCA focusses on radiochemistry methodology development, selection of biological targets and development of new PET tracers for these targets, preclinical in vivo evaluation of new PET tracers as well as good manufacturing practice (GMP)-compliant synthesis of PET tracers.
In 2019 we will move into the Amsterdam UMC Imaging Center equipped with a brand new lab for TCA according to current state of the art. At the Imaging Center all imaging modalities will come together and the synergy with the clinic will be further enhanced.
TCA collaborates with many national and international research institutes and pharmaceutical companies and is partner in several ITN-EU funded programs (PET3D, RadioMI).
VUmc wishes our staff to reflect the diversity of society and thus welcomes applications from all qualified candidates regardless of personal background.
Our consortium has assembled 6 radiopharmaceutical frontline academic and 10 non-academic partners to train the next generation of radiopharmaceutical scientists. Our training will be focused on an unmet scientific need for Parkinson’s Disease (PD). Fibril formation of protein α-synuclein is thought to be the hallmark for PD, but presently, there are no validated PET tracers available for visualization of pathogenic aggregates of this protein. Our scientific goal is to develop such tracer. A successful tracer will have a strong impact on PD-diagnosis and facilitate the development of effective disease modifying treatments. To reach our goals, it is necessary to train our early stage researchers in a highly interdisciplinary fashion spanning from chemistry, over biology, GMP and pharmacy to nuclear medicine.
Salary Scale PHD: 2336 tot 2992 euro gross when employed full-time (depending on qualifications and experience).
In addition we give a bonus of 8,3% of the year’s salary at the end of the year and 8% of the year’s salary as holiday bonus. VUmc employees can profit from a advantageous health care insurance and other benefits. For more information see our website.
According to the rules of the EU, PhD fellows working in a ITN program might have additional salary bonus as living and family allowance. These are to be established based on the personal situation of the candidate.
For Dutch citizens it is mandatory to provide a VOG (a declaration of good behaviour).
The application must include a motivation letter, a curriculum vitae, a list of peer reviewed publications, as well as possible letters of recommendation and diplomas.
Don’t hesitate to call us!
If you’re interested about this position, you can contact dr D.J. Vugts at +31204445699 or alternatively Prof. dr. A.D. Windhorst, via telephone number +31 20 444 9707.
If you need more information about the application procedure, contact Brend de Jong, corporate recruiter at 020-444 5635.
You can apply till 23 December 2018 by using the apply button.
Acquisition based on this vacancy is not appreciated.